Eric Schmidt FCA
Stock Analyst at Cantor Fitzgerald
(4.87)
# 331
Out of 4,595 analysts
43
Total ratings
51.2%
Success rate
81.9%
Average return
Main Sectors:
Stocks Rated by Eric Schmidt FCA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Initiated Coverage: Buy | n/a | $25.18 | - | 1 | Jul 23, 2026 | |
| BIIB Biogen | Initiated Coverage: Buy | $206 | $202.95 | +1.50% | 4 | Jun 22, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | n/a | $18.93 | - | 1 | Jun 2, 2026 | |
| LONA LeonaBio | Reiterated: Buy | n/a | $7.06 | - | 2 | Apr 7, 2026 | |
| GENB Generate Biomedicines | Initiated Coverage: Buy | n/a | $14.00 | - | 1 | Mar 24, 2026 | |
| SRRK Scholar Rock Holding | Maintained: Buy | n/a | $47.30 | - | 2 | Mar 19, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 → $74 | $18.55 | +298.92% | 4 | Dec 17, 2025 | |
| VSTM Verastem | Initiated Coverage: Buy | n/a | $5.80 | - | 1 | Oct 16, 2025 | |
| ALMS Alumis | Reiterated: Buy | n/a | $28.25 | - | 3 | Aug 14, 2025 | |
| BBIO BridgeBio Pharma | Initiated Coverage: Buy | n/a | $80.09 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $8.09 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.02 | n/a | 8 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $38.62 | n/a | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.12 | n/a | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.66 | n/a | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $30.02 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $14.47 | n/a | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.05 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $119.52 | n/a | 1 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $27.18 | n/a | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $33.81 | n/a | 1 | Nov 2, 2023 |
Dyne Therapeutics
Jul 23, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $25.18
Upside: -
Biogen
Jun 22, 2026
Initiated Coverage: Buy
Price Target: $206
Current: $202.95
Upside: +1.50%
Odyssey Therapeutics
Jun 2, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $18.93
Upside: -
LeonaBio
Apr 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.06
Upside: -
Generate Biomedicines
Mar 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $14.00
Upside: -
Scholar Rock Holding
Mar 19, 2026
Maintained: Buy
Price Target: n/a
Current: $47.30
Upside: -
Legend Biotech
Dec 17, 2025
Maintained: Buy
Price Target: $75 → $74
Current: $18.55
Upside: +298.92%
Verastem
Oct 16, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $5.80
Upside: -
Alumis
Aug 14, 2025
Reiterated: Buy
Price Target: n/a
Current: $28.25
Upside: -
BridgeBio Pharma
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $80.09
Upside: -
Aug 13, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $8.09
Upside: -
Jul 28, 2025
Reiterated: Buy
Price Target: n/a
Current: $13.02
Upside: n/a
Jul 25, 2025
Reiterated: Buy
Price Target: n/a
Current: $38.62
Upside: n/a
Jun 20, 2025
Reiterated: Hold
Price Target: n/a
Current: $8.12
Upside: n/a
Jun 2, 2025
Reiterated: Buy
Price Target: n/a
Current: $8.66
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $30.02
Upside: n/a
Mar 21, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $14.47
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $1.05
Upside: n/a
Apr 23, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $119.52
Upside: n/a
Apr 4, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $27.18
Upside: n/a
Nov 2, 2023
Initiated Coverage: Buy
Price Target: n/a
Current: $33.81
Upside: n/a